title: Tau-mediated nuclear depletion and cytoplasmic accumulation of SFPQ in Alzheimer's and Pick's disease.
abstract: Tau dysfunction characterizes neurodegenerative diseases such as Alzheimer's disease (AD) and frontotemporal lobar degeneration (FTLD). Here, we performed an unbiased SAGE (serial analysis of gene expression) of differentially expressed mRNAs in the amygdala of transgenic pR5 mice that express human tau carrying the P301L mutation previously identified in familial cases of FTLD. SAGE identified 29 deregulated transcripts including Sfpq that encodes a nuclear factor implicated in the splicing and regulation of gene expression. To assess the relevance for human disease we analyzed brains from AD, Pick's disease (PiD, a form of FTLD), and control cases. Strikingly, in AD and PiD, both dementias with a tau pathology, affected brain areas showed a virtually complete nuclear depletion of SFPQ in both neurons and astrocytes, along with cytoplasmic accumulation. Accordingly, neurons harboring either AD tangles or Pick bodies were also depleted of SFPQ. Immunoblot analysis of human entorhinal cortex samples revealed reduced SFPQ levels with advanced Braak stages suggesting that the SFPQ pathology may progress together with the tau pathology in AD. To determine a causal role for tau, we stably expressed both wild-type and P301L human tau in human SH-SY5Y neuroblastoma cells, an established cell culture model of tau pathology. The cells were differentiated by two independent methods, mitomycin C-mediated cell cycle arrest or neuronal differentiation with retinoic acid. Confocal microscopy revealed that SFPQ was confined to nuclei in non-transfected wild-type cells, whereas in wild-type and P301L tau over-expressing cells, irrespective of the differentiation method, it formed aggregates in the cytoplasm, suggesting that pathogenic tau drives SFPQ pathology in post-mitotic cells. Our findings add SFPQ to a growing list of transcription factors with an altered nucleo-cytoplasmic distribution under neurodegenerative conditions.
authors.affiliation: Alzheimer's and Parkinson's Disease Laboratory, Brain & Mind Research Institute, University of Sydney, Camperdown, New South Wales, Australia.
authors.forename: Yazi D
authors.initials: YD
authors.lastname: Ke
authors.forename: Yazi
authors.initials: Y
authors.lastname: Ke
authors.forename: Joe
authors.initials: J
authors.lastname: Dramiga
authors.forename: Ulrich
authors.initials: U
authors.lastname: Schütz
authors.forename: Jillian J
authors.initials: JJ
authors.lastname: Kril
authors.forename: Lars M
authors.initials: LM
authors.lastname: Ittner
authors.forename: Hannsjörg
authors.initials: H
authors.lastname: Schröder
authors.forename: Jürgen
authors.initials: J
authors.lastname: Götz
mesh_terms: D000544:Alzheimer Disease / Q000235:genetics* / Q000378:metabolism; D000679:Amygdala / Q000378:metabolism / Q000473:pathology; D000818:Animals; D001253:Astrocytes / Q000378:metabolism / Q000473:pathology; D002454:Cell Differentiation / Q000187:drug effects / Q000235:genetics; D045744:Cell Line, Tumor; D003593:Cytoplasm / Q000378:metabolism; D015536:Down-Regulation; D018728:Entorhinal Cortex / Q000378:metabolism / Q000503:physiopathology; D057174:Frontotemporal Lobar Degeneration / Q000235:genetics* / Q000378:metabolism; D020869:Gene Expression Profiling; D006801:Humans; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D016685:Mitomycin / Q000494:pharmacology; D009474:Neurons / Q000378:metabolism / Q000473:pathology; D000072670:PTB-Associated Splicing Factor; D020774:Pick Disease of the Brain / Q000235:genetics* / Q000378:metabolism; D016601:RNA-Binding Proteins / Q000235:genetics* / Q000378:metabolism; D014212:Tretinoin / Q000494:pharmacology; D016875:tau Proteins / Q000235:genetics* / Q000378:metabolism
chemical_list: D000072670:PTB-Associated Splicing Factor; D016601:RNA-Binding Proteins; D016875:tau Proteins; D016685:Mitomycin; D014212:Tretinoin